03 September 2010
Keywords: Shire, USA, Replagal, Velaglucerase, Fabry disease, Gaucher disease, BLA filing
Article | 23 December 2009
Specialty biopharmaceutical company Shire says that it has submitted a Biologics License Application (BLA) with the USA’s Food and Drug Administration for Replagal (agalsidase alfa), its enzyme replacement therapy for Fabry disease. The drug first received marketing authorization in the European Union in 2001, and is approved for the treatment of Fabry disease in 45 countries.
T Enjoying this article? To continue reading you need to login, take a FREE trial or subscribe.
FREE unlimited, no obligation access to The Pharma Letter website for 30 days, normally worth £60!
Sign up in less than 60 seconds...no payment needed
Take a no obligations 30 day trial.
Only one trial per user. Find out more details
Subscriptions are £60 per month, pay as you go.
Find out more details.